Biolegend, 317434, Brilliant Violet 421™ anti-human CD4 Antibody, 100tests

CD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16.
100tests
Verified Reactivity: Human, Cynomolgus, Rhesus
Reported Reactivity: Chimpanzee
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Human peripheral T cells
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested ICC - Verified
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317453 and 317454). In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.9
Application References(PubMed link indicates BioLegend citation): Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. 76:4061. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed Cicin-Sain L, et al. 2010. J. Immunol. 184:6739. PubMed Rosenzweig M, et al. 2001. J. Med. Primatol. 30:36. Linder J, et al. 1987. Am. J. Pathol. 127:1. Boche D, et al. 1999. J. Neurovirol. 5:232. (IHC) Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. USA. 76:4061. (Immunogen) Lederman S, et al. 1991. Mol Immunol. 28:1171-81.
Product Citations: Bolton D, et al. 2016. J Virol. 90: 1321 - 1332. PubMed Bolton D, et al. 2017. PLoS Pathogens. 13(6):e1006445. PubMed Xu H, et al. 2019. Cell Stem Cell. 24:566. PubMed van Os BW, et al. 2023. Eur Heart J Open. 3:oead013. PubMed Hu X, et al. 2023. Nat Commun. 14:2020. PubMed Kim JH, et al. 2020. Sci Rep. 10:1835. PubMed Ellis GI, et al. 2022. Cell Rep Med. 3:100614. PubMed Wang J, et al. 2022. Cell Discov. 8:136. PubMed Nozawa K, et al. 2023. Front Immunol. 13:1084960. PubMed Xu Y, et al. 2022. Bio Protoc. 12:e4354. PubMed Saggau C, et al. 2022. Immunity. :. PubMed Hoang TN, et al. 2021. Cell. 184:460. PubMed Wilson PA, et al. 2021. PLoS One. 16:e0258316. PubMed Thaker YR, et al. 2022. Front Oncol. 12:884196. PubMed Bacher P, et al. 2020. Immunity. . PubMed Rodriguez-García A, et al. 2020. Mol Ther. 28:548. PubMed Bacher P et al. 2019. Cell. 176(6):1340-1355 . PubMed Leslie G, et al. 2016. PLoS Pathog. 12:e1005983. PubMed Liu Y, et al. 2018. JCI Insight. 3:. PubMed Martínez-Sabadell A, et al. 2022. STAR Protoc. 3:101712. PubMed García-Arriaza J, et al. 2015. J Virol. 89: 8525-8539. PubMed Etxeberria I, et al. 2020. Cancer Cell. 36(6):613-629. PubMed Li H, et al. 2019. Cell. 176:775. PubMed Cao W, et al. 2017. Immunity. 47:1182. PubMed Lisovsky I, et al. 2015. J Virol. 89: 9909 - 9919. PubMed Minagawa A, et al. 2018. Cell Stem Cell. 1.548611111. PubMed Hoang TN, et al. 2020. bioRxiv. . PubMed Cheng C, et al. 2020. Cell Reports. 32(5):107981. PubMed Di Genua C, et al. 2020. Cancer Cell. 37(5):690-704.e8.. PubMed Medvec AR, et al. 2018. Mol Ther Methods Clin Dev. 8:65. PubMed Weaver JD, et al. 2022. Oncoimmunology. 11:2141007. PubMed Kong R, et al. 2019. Cell. 178:567. PubMed Ryan E, et al. 2016. PLoS Pathog. 12: 1005412. PubMed Oh DY, et al. 2020. Cell. 181:1612. PubMed Ellis GI, et al. 2022. STAR Protoc. 3:101784. PubMed Marelli S, et al. 2020. Elife. :9. PubMed Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed Lickliter JD, et al. 2020. Drug Des Devel Ther. 14:1177. PubMed Dawson NA, et al. 2019. JCI Insight. 4:6. PubMed Naamati A, et al. 2019. Elife. 8:e41431. PubMed Georg P, et al. 2022. Cell. 185:493. PubMed Iwata A, et al. 2017. Nat Immunol. 18:563. PubMed Sehgal R, et al. 2022. Front Immunol. 13:828949. PubMed Harper J, et al. 2021. Nat Commun. 12:2866. PubMed Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed Abdel-Mohsen M, et al. 2016. PLoS Pathog. 12: 1005677. PubMed
RRID: AB_11150413 (BioLegend Cat. No. 317433) AB_2562134 (BioLegend Cat. No. 317434)
Structure: Ig superfamily, type I transmembrane glycoprotein, 55 kD
Distribution: T cell subset, majority of thymocytes, monocytes/macrophages
Function: MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor
Ligand/Receptor: MHC class II molecules, HIV gp120, IL-16
Cell Type: Macrophages, Monocytes, T cells, Thymocytes, Tregs
Biology Area: Immunology
Molecular Family: CD Molecules
Antigen References: 1. Center D, et al. 1996. Immunol. Today 17:476. 2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.
Gene ID: 920
UniProt: View information about CD4 on UniProt.org
Clone: OKT4
Regulatory Status: RUO
Workshop: HCDM listed
Other Names: T4
Isotype: Mouse IgG2b, κ
Q: I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
A: TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Q: What is the F/P ratio range of our BV421™ format antibody reagents?
A: It is lot-specific. On average it ranges between 2-4.